# US 2024/0189237 A1 · Formulation and method for treatment of urinary system disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189237 A1
- Document ID: US20240189237A1
- Status: Published application
- Kind: A1
- Application number: 18/285,645
- Filed: 2021-04-07
- Published: 2024-06-13
- Earliest claimed: 2021-04-07
- Assignees: Watershed Medical, Inc.
- Applicants: Watershed Medical Inc
- Inventors: Christopher R. KINSELLA, Jr.; Saniya ALI; Clay Justin NOLAN; Rush Lloyd BARTLETT, II
- Web page: https://patentgrep.com/patent/US20240189237A1

## CPC

- A61K 9/1676: {having a drug-free core with discrete complete coating layer containing drug (adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921)}
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1641: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
- A61K 31/546: containing further heterocyclic rings, e.g. cephalothin
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 33/38: Silver; Compounds thereof
- A61P 13/10: of the bladder
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides a formulation and method for the treatment of urinary system disorders, wherein the formulation comprises a controlled release drug delivery system for intravesicular administration to a patient. Controlled release microparticles in the formulation are comprised of a pharmacologically active agent and a controlled release carrier, where the microparticles are buoyant in urine. Microparticle buoyancy in urine ensures that the formulation continues to release the active agent into a patient's bladder throughout the duration of an extended drug delivery time period. Methods of treating urinary system disorders by intravesicular administration of the microparticle formulation to a subject are also provided, and include methods of treating urinary system infections, bladder cancer, incontinence, and other urinary system disorders.

## Claims

### Claim 1

A controlled release pharmaceutical formulation for intravesical administration to a subject, the formulation comprising a population of microparticles having a mean diameter of 500 nm to 2000 μm and comprised of 2.5 wt. % to 95 wt. % of a pharmacologically active agent and 5 wt. % to 97.5 wt. % of a controlled release carrier,
wherein the active agent, carrier, and relative amounts of the active agent and carrier in the microparticles render the microparticles buoyant in urine.

### Claim 2 (depends on 1)

The formulation of claim 1, wherein the microparticles have a mean specific gravity of less than 1.03.

### Claim at position 3

-4. (canceled)

### Claim 5 (depends on 4)

The formulation of claim 4, wherein the carrier provides for controlled release of the pharmacologically active agent in the urinary system and/or bladder.

### Claim at position 5

-7. (canceled)

### Claim 8 (depends on 1)

The formulation of claim 1, wherein the carrier is comprised of a matrix and the pharmacologically active agent is dispersed therein.

### Claim 9 (depends on 1)

The formulation of claim 1, wherein the carrier comprises a coating on a core that comprises the pharmacologically active agent dispersed therein.

### Claim 10 (depends on 1)

The formulation of claim 1, wherein the carrier gradually dissolves, degrades, or erodes in urine to release the pharmacologically active agent from the microparticles.

### Claim 11 (depends on 1)

The formulation of claim 1, wherein the carrier comprises a fatty acid, fatty alcohol, fatty acid ester, phospholipid, sterol, polyethylene glycol alkyl ether, polyoxyethylene-polyoxypropylene block copolymer, chitosan, or bile salt.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The formulation of claim 1, wherein the carrier comprises a fatty acid ester, the fatty acid ester comprised of a lower alcohol fatty acid ester, a triglyceride, a monoglyceride, a triglyceride, a polyglycerized fatty acid, a propylene glycol fatty acid ester, a polyethoxylated fatty acid, a polyethoxylated glyceryl fatty acid ester, a sorbitan fatty acid ester, or a hydroxyacid diester.

### Claim 14 (depends on 13)

The formulation of claim 13, wherein the fatty acid ester is a triglyceride selected from glyceryl tributyrate, glyceryl tricaproate, glyceryl tricaprylate, glyceryl tricaprate, glyceryl triundecanoate, glyceryl trilaurate, glyceryl trimyristate, glyceryl tripalmitate, glyceryl tristearate, glyceryl trimyristoleate, and glyceryl trioleate.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The formulation of claim 1, wherein the carrier comprises a surfactant selected from sodium lauryl sulfate, cetyltrimethyl-ammonium bromide, benzalkonium chloride, 2-phenoxyethanol, and benzoyl alcohol.

### Claim 17 (depends on 1)

The formulation of claim 1, wherein the pharmacologically active agent comprises one or more of an anti-infective agent, an anesthetic agent, an analgesic agent, a diuretic, an anti-inflammatory agent, a coagulant or an anti-coagulant, a chemotherapeutic agent, an agent for the treatment of incontinence, an angiotensin-aldosterone system (RAAS) inhibitor, an agent for treating kidney stones, and a contrast agent for diagnostics and monitoring.

### Claim at position 16

-23. (canceled)

### Claim 24 (depends on 5)

The formulation of claim 5, wherein the controlled release carrier provides sustained release of the pharmacologically active agent in the bladder over a drug delivery time period of 2 hours to six months.

### Claim 25

(canceled)

### Claim 26 (depends on 24)

The formulation of claim 24, wherein the controlled release carrier provides for approximately zero order release of the pharmacologically active agent in the bladder.

### Claim 27 (depends on 1)

The formulation of claim 1, further including a liquid vehicle in which the population of microparticles is dispersed, the liquid vehicle comprised of a viscosity adjusting agent, a tonicity adjusting agent, a buffer, and a dispersant.

### Claim at position 21

-34. (canceled)

### Claim 35

A method of treating a urinary system disorder in a subject, the method comprising intravesical administration of a formulation comprised of microparticles having a mean diameter of 50 nm to 2000 μm, 2.5 wt. % to 95 wt. % of a pharmacologically active agent, and 5 wt. % to 97.5 wt. % of a controlled release carrier,
wherein the microparticles are buoyant in urine, and
wherein the formulation is at least partially retained by the bladder for a duration of a drug delivery time period upon which the active agent is released.

### Claim 36 (depends on 35)

The method of claim 35, wherein the microparticles have a mean specific gravity of less than 1.03.

### Claim 37

(canceled)

### Claim 38 (depends on 35)

The method of claim 35, wherein the pharmacologically active agent comprises an anti-infective agent, an anesthetic agent, an analgesic agent, a diuretic, an anti-inflammatory agent, a coagulant or an anti-coagulant, a chemotherapeutic agent, an agent for the treatment of incontinence, an RAAS inhibitor, an agent for treating kidney stones, a contrast agent for diagnostics and monitoring, or a combination thereof.

### Claim 39

(canceled)

### Claim 40 (depends on 39)

The method of claim 39, wherein the urinary system disorder is an infection, cancer, incontinence, a kidney stone or a urinary tract infection.

### Claim at position 28

-51. (canceled)

### Claim 52 (depends on 35)

The method of claim 35, wherein the controlled release comprises (a) sustained release, (b) bolus dose followed by sustained release or (c) zero order release.

### Claim at position 30

-57. (canceled)

### Claim 58 (depends on 35)

The method of claim 35, wherein a unit dose of the formulation is administered to the subject, the unit dose comprising 60 mg to 5 g of the pharmacologically active agent.

### Claim at position 32

-67. (canceled)
